Literature DB >> 16723621

Imatinib mesylate--uncovering a fast track to adaptive immunity.

Mark J Smyth1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16723621     DOI： 10.1056/NEJMcibr061878

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  7 in total

1.  Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia.

Authors:  Paul A Carpenter; David S Snyder; Mary E D Flowers; Jean E Sanders; Theodore A Gooley; Paul J Martin; Frederick R Appelbaum; Jerald P Radich
Journal:  Blood       Date:  2007-04-01       Impact factor: 22.113

2.  Immune cells in primary and metastatic gastrointestinal stromal tumors (GIST).

Authors:  Silke Cameron; Marieke Gieselmann; Martina Blaschke; Giuliano Ramadori; Laszlo Füzesi
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

Review 3.  Targeting immune suppressing myeloid-derived suppressor cells in oncology.

Authors:  Johnny Kao; Eric C Ko; Samuel Eisenstein; Andrew G Sikora; Shibo Fu; Shu-Hsia Chen
Journal:  Crit Rev Oncol Hematol       Date:  2010-03-20       Impact factor: 6.312

Review 4.  Small-molecule protein kinase inhibitors and their effects on the immune system: implications for cancer treatment.

Authors:  Patrick A Ott; Sylvia Adams
Journal:  Immunotherapy       Date:  2011-02       Impact factor: 4.196

5.  Imatinib treatment induces CD5+ B lymphocytes and IgM natural antibodies with anti-leukemic reactivity in patients with chronic myelogenous leukemia.

Authors:  Silvia Catellani; Ivana Pierri; Marco Gobbi; Alessandro Poggi; Maria Raffaella Zocchi
Journal:  PLoS One       Date:  2011-04-18       Impact factor: 3.240

6.  Imatinib mesylate can help to direct natural immunity toward an anti-leukemic reactivity by acting on the bone marrow microenvironment.

Authors:  Alessandro Poggi; Maria Raffaella Zocchi
Journal:  Oncoimmunology       Date:  2012-03-01       Impact factor: 8.110

7.  Hepatitis B Virus Reactivation in Gastrointestinal Stromal Tumor Patients Treated With Imatinib.

Authors:  Tianxiang Lei; Fengbo Tan; Zhouhua Hou; Peng Liu; Xianhui Zhao; Heli Liu
Journal:  Front Oncol       Date:  2021-01-22       Impact factor: 6.244
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.